EGFR and Cholecystitis: The motesanib 75-mg BID dosing cohort was suspended when an increased risk of cholecystitis was found at that dose level in other studies of motesanib as a monotherapy [16,17] or in combination with carboplatin/paclitaxel and an EGFR inhibitor [20].